Occlutech Memenangkan Putusan Paten Melawan St Jude-AGA Medical di Italia

AsiaNet 47022

JENA, Jerman, 28 Oktober /PRNewswire-AsiaNet/ —

Occlutech, perusahaan terkemuka di Eropa yang mengembangkan occluder
septum seperti perangkat PFO dan ASD serta implan (cangkok) jantung inovatif
lainnya yang memerlukan sedikit tindakan, hari ini mengumumkan telah mendapat
putusan yang menguntungkan dalam litigasi (proses hukum) paten dengan St
Jude-AGA Medical dari Pengadilan Negeri Milan di Italia.

Dalam putusannya, pengadilan menyatakan bahwa Occlutech tidak melanggar
bagian Italia dari paten EP0808138 sebagaimana yang dituduhkan oleh St Jude-AGA
Medical.

Putusan itu kembali menegaskan bahwa Occlutech memiliki teknologi orisinil
unik yang tidak melanggar paten AGA yang diajukan di Italia.

Tor Peters, CEO Occlutech GmbH berkata; “Kami telah mengembangkan dan
mematenkan teknologi unik kami selama bertahun-tahun. Kami yakin bahwa ketika
diterapkan pada occluder jantung dan banyak implan lain yang memerlukan sedikit
tindakan, perangkat tersebut merupakan langkah besar ke depan yang memberi para
pasien keuntungan signifikan.”

Sebelumnya, pengadilan di Inggris, Belanda, Jerman dan Swedia mencapai
kesimpulan yang sama seperti di Italia. Putusan di Inggris dan Jerman terkait
dengan paten ini telah final. Putusan banding di Swedia dan Belanda telah
diajukan oleh AGA. Putusan banding di Italia masih dapat diajukan.

Perangkat oklusi digunakan untuk mengobati penyakit jantung struktural,
termasuk cacat dan kelainan jantung struktural seperti Atrial Septal Defects,
(ASD), dan Patent Foramen Ovale (PFO, saluran yang tidak seharusnya ada di
antara dua arteri jantung, yang dialami sebanyak lebih dari 25% populasi),
dalam prosedur tanpa pembedahan yang memerlukan sedikit tindakan. Pasar
occluder PFO diharapkan akan meluas secara signifikan karena hubungan antara
PFO dan stroke, yang merupakan penyebab kematian terbesar ketiga, serta migren
parah dapat semakin didokumentasikan dengan baik.

SUMBER: Occlutech GmbH


Occlutech Wins Patent Ruling Against St Jude-AGA Medical in Italy

JENA, Germany, October 28 /PRNewswire-AsiaNet/ —

Occlutech, a leading European developer of septum occluders such as PFO and ASD devices as well as other innovative, minimally invasive cardiac implants, today announced that it got a favorable ruling in patent litigation with St Jude-AGA Medical from the District Court of Milan in Italy.

In the ruling, the court stated that Occlutech is not infringing the Italian part of patent EP0808138 as alleged by St Jude-AGA Medical.

The ruling again confirms that Occlutech has a unique, original technology that does not infringe the AGA-patent brought forward in Italy.

Tor Peters, CEO of Occlutech GmbH says; “We have spent years developing and patenting our unique technology. We are convinced that when applied in cardiac occluders and many other minimally invasive implants it is a big step forward offering patients significant advantages.”

Earlier, courts in The UK, The Netherlands, Germany & Sweden have come to the same conclusion as in Italy. The rulings in the UK and Germany related to this patent are final. The Swedish and Dutch rulings have been appealed by AGA. The Italian ruling can still be appealed.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart’s two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

SOURCE: Occlutech GmbH